EI
CRBP icon

EAM Investors’s Corbus Pharmaceuticals CRBP Stock Holding History

EAM Investors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,609
Closed -$571K – 263
2024
Q2 		$571K Buy
+12,609
New +$530K 0.09% 221
2017
Q2 		– Sell
-5,219
Closed -$1.29M – 311
2017
Q1 		$1.29M Sell
5,219
-5,532
-51% -$1.36M 0.2% 179
2016
Q4 		$2.73M Buy
+10,751
New +$2.46M 0.36% 139

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

EAM Investors's CRBP Position: Q3 2024 in Review

EAM Investors sold out of Corbus Pharmaceuticals (CRBP) in Q3 2024, closing a stake of 12,609 shares — an estimated $571K sold.

EAM Investors first reported a position in CRBP in Q4 2016 and held it in 3 quarters. The position peaked at $2.73M in Q4 2016. 107 funds tracked by Wall St. Rank hold CRBP as of Q3 2024.

  • EAM Investors reported no remaining Corbus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • EAM Investors sold 12,609 Corbus Pharmaceuticals shares in Q3 2024, an estimated $571K.
  • EAM Investors first reported a position in Corbus Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • EAM Investors's Corbus Pharmaceuticals position peaked at $2.73M in Q4 2016.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2024.

Based on EAM Investors's 13F filing for Q3 2024, filed 13 Nov 2024.